期刊
BRIEFINGS IN FUNCTIONAL GENOMICS
卷 18, 期 2, 页码 133-139出版社
OXFORD UNIV PRESS
DOI: 10.1093/bfgp/ely027
关键词
CTLA-4; PD-1; PD-L1; immune checkpoint blockade; immunogenomics; MMR deficiency; POLE; somatic; mutation; resistance to checkpoint blockade; neoantigen
资金
- National Institute of Health/National Cancer Institute [U01CA188387-01]
- University of Hawaii Pilot Awards
- University of Hawaii Star-up fund
Immune checkpoints have been the subject of a wave of new studies. Among these checkpoints are tytotoxic T-lymphocyte-associated antigen 4, checkpoints programmed death-1 and programmed death-ligand 1; their blockades have been approved by the Food and Drug Administration for therapy of melanoma and other types of cancers. Immunogenomics, which combines the latest nucleic acid sequencing strategy with immunotherapy, provides precise information about genomic alterations (e.g. mutations) and enables a paradigm shift of immune checkpoint therapy from tumor types to molecular signatures. Studying these critical checkpoints in relation to genomic mutations and neoantigens has produced groundbreaking results. This article examines these studies and delves into the relationships between immune checkpoint blockade and tumors harboring certain genomic mutations. Moreover, this article reviews recent studies on resistance to immune checkpoint therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据